Magrietha Mallinson, Global Vertical Lead, Health at DP World discusses unlocking the potential of Africa's pharmaceutical market in our latest EPM Online insight.
In our first interview series of the year with Lonza, we spoke with Dr. Simon Wagschal, Associate Director, Advanced Chemistry Technologies, Lonza Small Molecules Global R&D and Dr. Aaron Johnson, Manager, Cheminformatics & Data Science, Lonza.
BBI Solutions OEM Limited (BBI) has announced the successful closing of the acquisition of IBEX Technologies Inc. (IBEX), a leading developer and manufacturer of high-precision enzymes and diagnostic solutions located in Montréal, Québec.
The UK MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion) to treat adult patients with complicated infections of the urinary tract.
The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalisation due to heart failure or all-cause mortality for empagliflozin versus placebo.
There is a real opportunity for AI to maximise Life Sciences companies’ investment in regulatory data management. ArisGlobal’s Agnes Cwienczek & Renato Rjavec set out practical examples of AI and Generative AI delivering tangible benefits.
Bespak have announced the completion of the transaction to separate Recipharm’s former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company.
Blackstone have announced a new collaboration with Moderna through a development and commercialisation funding agreement where funds managed by Blackstone Life Sciences and will provide up to $750 million to fund Moderna’s influenza program.
MSD have announced that the U.S. FDA has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension.
Otsuka Pharmaceutical Europe and H. Lundbeck A/S have announced that the European Commission has approved Abilify Maintena 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the treatment of schizophrenia.
Corteria Pharmaceuticals have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure.
